Search

The past two decades have been marked by the design of a great variety of innovative biological agents, the clinical introduction of which could substantially improve the results of treatment for rheumatic diseases. At the same time, there are a larger number of reports on their administration-associated adverse events, often paradoxical ones (these drugs indicated in many autoimmune processes may induce similar autoimmune processes).